###begin article-title 0
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
Immunophenotypes of macular corneal dystrophy in India and correlation with mutations in CHST6
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
To determine the immunophenotypes of macular corneal dystrophy (MCD) in Indian patients and to correlate them with mutations in the carbohydrate 6-sulfotransferase (CHST6) gene.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
Sixty-four patients from 53 families with MCD that were previously screened for mutations in CHST6 were included in an immunophenotype analysis. Antigenic keratan sulfate (AgKS) in serum as well as corneal tissue was evaluated in 31 families. Only cornea was evaluated in 11 families, and only serum was evaluated in 11 families. AgKS was detected in formalin-fixed, paraffin-embedded corneal sections by immunohistochemistry and in serum by ELISA using a monoclonal antibody against sulfated forms of KS in patients with MCD as well as normal controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
Analysis of corneal and/or serum AgKS disclosed MCD type I (27 families), MCD type IA (5 families), and MCD type II (3 families) in the cases studied. An additional 10 families were either MCD type I or MCD type IA since only serum AgKS data were available. Seven families manifested atypical immunophenotypes since the corneal AgKS expression was either of MCD type I or MCD type IA, but serum AgKS levels ranged from 19 ng/ml to 388 ng/ml. More than one immunophenotype was detected amongst siblings in two families. Each immunophenotype was associated with mutational heterogeneity in CHST6.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 377 382 377 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
MCD type I was the predominant immunophenotype in the Indian population studied followed by MCD type IA and then MCD type II. We detected further immunophenotypic heterogeneity by finding atypical patterns of AgKS reactivity in a subset of families. There were no simple correlations between immunophenotypes and specific mutations in CHST6, suggesting that factors other than CHST6 mutations may be contributing to the immunophenotypes in MCD.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 811 812 811 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 886 887 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 968 973 968 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 1068 1069 1068 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 666 674 <span type="species:ncbi:9606">patients</span>
Macular corneal dystrophy (MCD; OMIM ) is an autosomal recessive disorder characterized clinically by bilateral diffuse clouding of the corneal stroma and the presence of grayish-white, punctate opacities especially in the superficial cornea. Histologically, the cornea in MCD is characterized by the accumulation of extracellular deposits in the stroma and Descemet membrane as well as by intracellular storage of similar material in the keratocytes and corneal endothelium. The deposits stain with Alcian blue and other histochemical methods for glycosaminoglycans (GAGs) [1]. Biochemical studies based on organ cultures of corneas as well as analyses of serum in patients with MCD suggested that the basic defect in MCD lies in a sulfotransferase specific for sulfation of keratan sulfate (KS) proteoglycan [2-7]. Molecular genetic studies on MCD led to the mapping of the MCD gene [8] and subsequently to the identification of the carbohydrate 6-sulfotransferase (CHST6) gene, which codes for corneal N-acetyl glucosamine 6-sulfotransferase, as the cause for MCD [9].
###end p 11
###begin p 12
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 841 862 841 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Erythrina crystagalli</italic>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 975 976 975 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1050 1055 1050 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 1172 1177 1172 1177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 1290 1291 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1586 1591 1586 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 1713 1719 1713 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6 </italic>
###xml 1734 1736 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 1737 1739 1737 1739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 1545 1553 <span type="species:ncbi:9606">patients</span>
Although MCD is clinically homogeneous, three immunophenotypes have been recognized based on the reactivity of the cornea and serum in patients with MCD to a monoclonal antibody, 5D4, which is specific for highly sulfated epitopes on KS [10-13]. MCD type I is characterized by the absence or very low levels of antigenic keratan sulfate (AgKS) in the cornea and serum. MCD type II is characterized by the presence of normal or slightly reduced levels of AgKS in serum and an immunohistochemical reactivity for AgKS in the corneal stroma, keratocytes, Descemet membrane, and endothelial cells [10]. In addition, a third immunophenotype (MCD type IA) is characterized by an absence or very low level of serum AgKS accompanied by detectable AgKS reactivity in keratocytes [11]. The deposits in MCD type I were further shown to be unsulfated by Erythrina crystagalli agglutinin labeling, which recognizes unsulfated keratan sulfate proteoglycan (KSPG) [13]. Akama and coworkers [9] suggested that MCD types I and II were distinguishable by the nature of CHST6 mutations. They observed that MCD type II was associated with a deletion or rearrangement of the upstream region of CHST6 and proposed that MCD type II is characterized by an absence of coding region mutations in one or both alleles [9]. However, deviations from this pattern have been observed in subsequent studies [14,15]. Despite the fact that the immunophenotypes of MCD do not seem to be clinically relevant, we wanted to determine the prevalence of different MCD subtypes in Indian patients and to evaluate the relation of CHST6 mutations with the aforementioned immunophenotypes in a series of 53 Indian families with MCD in whom mutational data on CHST6 was available [16,17].
###end p 12
###begin title 13
Methods
###end title 13
###begin p 14
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 658 663 658 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 213 225 <span type="species:ncbi:9606">participants</span>
###xml 280 291 <span type="species:ncbi:9606">participant</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 561 569 <span type="species:ncbi:9606">patients</span>
The study had the approval of the Institutional Review Board of the L. V. Prasad Eye Institute (Hyderabad, India) and conformed to the tenets of the Declaration of Helsinki. Informed consent was obtained from all participants, and 4 ml of peripheral blood was collected from each participant for serum analysis of AgKS. The diagnosis of MCD was based on the distinct clinical features (as described previously [16]), and in 48 patients this was confirmed by a histopathologic examination of the excised corneal buttons obtained at penetrating keratoplasty. All patients included in the present study were from the cohort previously screened for mutations in CHST6 [16,17].
###end p 14
###begin p 15
###xml 760 762 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 262 267 <span type="species:ncbi:10090">mouse</span>
###xml 407 412 <span type="species:ncbi:10090">mouse</span>
###xml 964 972 <span type="species:ncbi:9606">patients</span>
Immunohistochemistry was performed on 4 mu thick sections of paraffin-embedded formalin-fixed corneas from 48 MCD patients from 42 families (55 total corneas). Monoclonal primary antibody directed specifically against sulfated epitopes present on KS (1/20/5-D-4 mouse IgG; ICN Pharmaceuticals Inc., Irvine, CA) was used for detection of AgKS in the cornea. The secondary antibody used was biotinylated anti-mouse IgG (DakoCytomation, Glostrup, Denmark). Detection was done by the avidin-biotin complex immunoperoxidase technique in which avidin-conjugated peroxidase binds to the biotinylated antibody followed by detection of peroxidase after the addition of a suitable substrate, 3,3'-diaminobenzidine tetrahydrochloride (DAB; Sigma-Aldrich, St. Louis, MO) [18]. The primary antibody was used at a dilution of 1:700, which was determined as the optimum dilution by testing different antibody dilutions using corneas from positive (normal) controls that included patients with congenital hereditary endothelial dystrophy 2 (CHED2) or granular corneal dystrophy (GCD) in which KS is expected to be normal. As a negative control, the primary antibody was omitted and phosphate-buffered saline was used. Interpretations of immunohistochemical assays were made independently by four investigators, each masked to the findings of the others.
###end p 15
###begin title 16
Estimation of serum AgKS
###end title 16
###begin p 17
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Serum AgKS levels were determined in 51 MCD patients from 42 families and five unaffected relatives from 5 families by the enzyme-linked immunosorbent assay (ELISA) using the 1/20/5-D4 anti-KS monoclonal antibody as described previously [19]. Serum AgKS levels that were less than or equal to 8 ng/ml were interpreted as MCD types I/IA and levels of 100 ng/ml or above as normal or MCD type II.
###end p 17
###begin title 18
Results
###end title 18
###begin title 19
Immunophenotypes
###end title 19
###begin p 20
###xml 208 219 208 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1A-C</xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
Fifty-three families with MCD (64 patients) were evaluated for the AgKS reactivity of their corneal tissue and/or serum. Representative corneas showing the three different immunophenotypes are illustrated in Figure 1A-C. Levels of AgKS were assessed in both the cornea and serum of 31 families (35 patients) and in either cornea or serum in 22 families.
###end p 20
###begin p 21
###xml 193 194 193 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 274 275 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 373 374 373 374 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Immunophenotypes of MCD. Light microscopic images of representative corneas show different immunophenotypes of MCD (stained with diaminobenzidine [DAB], counterstained with hematoxylin-eosin). A: A cornea with the absence of detectable AgKS is shown (MCD type I; DAB; 40X). B: A cornea is shown with reactivity to AgKS only in stromal keratocytes (MCD type IA; DAB; 100X). C: A cornea is shown with AgKS detected throughout the stroma (MCD type II; DAB; 100X). Arrowheads point to the deposits in stromal keratocytes.
###end p 21
###begin p 22
###xml 109 116 109 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 423 430 423 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 67 75 <span type="species:ncbi:9606">patients</span>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
Of these, AgKS levels corresponding to MCD type I were found in 31 patients from 27 families (patients 1-31; Table 1) based on analyses of both the cornea and serum in at least one affected individual (20 families) and of only the cornea (7 families). More than one individual was available for this study in two families, and different members within each family showed similar patterns of AgKS (patients 21-22 and 28-31; Table 1).
###end p 22
###begin title 23
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Immunophenotypes and associated mutations in patients with MCD.
###end title 23
###begin p 24
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 274 276 274 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 389 397 <span type="species:ncbi:9606">patients</span>
Details of serum and corneal AgKS reactivity, associated CHST6 mutations and corresponding MCD immunophenotypes are listed for all patients studied. Reactivity to AgKS in cornea is denoted as present (+ve) or absent (-ve). Mutations in the protein are as described earlier [16,17]. Members of the same family are denoted by letters A-H in superscripts. The sharp (hash mark '#') indicates patients that had both corneas evaluated.
###end p 24
###begin p 25
###xml 37 44 37 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 165 172 165 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 219 227 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
Five families (7 patients [# 32-38]; Table 1) had a pattern corresponding with MCD type IA as assessed by AgKS reactivity in the cornea or in both cornea and serum (Table 1). Two families each had two affected members (patients 32, 33 and patients 37,38) who showed the same immunophenotypes.
###end p 25
###begin p 26
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 49 57 <span type="species:ncbi:9606">patients</span>
MCD type II was found in two unrelated patients (patients 39, 40) as indicated by corneal AgKS reactivity.
###end p 26
###begin p 27
###xml 267 274 267 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 329 337 <span type="species:ncbi:9606">patients</span>
###xml 410 417 <span type="species:ncbi:9606">patient</span>
###xml 458 465 <span type="species:ncbi:9606">patient</span>
Eleven families (13 patients) were grouped into immunophenotypes based only on serum levels on AgKS since corneal tissues were unavailable. The serum AgKS levels in 10 families (11 patients) were less than 8 ng/ml, corresponding to MCD types I or IA (patients 43-53; Table 1) whereas in one family with two affected individuals (patients 41 and 42; Table 1), serum AgKS corresponded to MCD type II (105 ng/ml; patient 41) or possibly to an atypical pattern (patient 42; 42 ng/ml).
###end p 27
###begin p 28
###xml 237 244 237 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
Apart from the three immunophenotypes mentioned above, there were seven families (7 patients) who showed AgKS reactivity that did not conform to any of the three types described and were therefore considered as atypical (patients 54-60; Table 1). These included four patients from four families with no detectable AgKS in the cornea (MCD type I pattern) and serum AgKS levels ranging from 19ng/ml to 63 ng/ml. The remaining three patients had detectable AgKS only in keratocytes (similar to MCD type IA) with serum AgKS levels ranging from 95 ng/ml to 388 ng/ml. Serum levels of AgKS in the three patients mentioned above are in the range of values for MCD type II.
###end p 28
###begin p 29
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 114 121 114 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 356 363 356 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 577 584 577 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 667 678 667 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A,B</xref>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 215 222 <span type="species:ncbi:9606">patient</span>
###xml 290 297 <span type="species:ncbi:9606">patient</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 426 433 <span type="species:ncbi:9606">patient</span>
###xml 514 519 <span type="species:ncbi:9606">child</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
Different immunophenotypes associated with the same CHST6 mutation within a family were observed in two families (Table 1). Two members (patients 60, 61) from one family showed either an 'atypical' immunophenotype (patient 60, mentioned above) or a corneal immunoreactivity of MCD type IA (patient 61). In the second family, three members (patients 62-64; Table 1) were evaluated for both serum and corneal AgKS. The proband (patient 62) had the MCD type II phenotype whereas the two other members, the spouse and child (patients 63, 64), had MCD types IA and I, respectively (Table 1). Photomicrographs of corneal sections of two members of this family are shown in Figure 2A,B.
###end p 29
###begin p 30
###xml 80 81 80 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 203 204 203 204 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 386 393 386 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 104 111 <span type="species:ncbi:9606">patient</span>
###xml 227 234 <span type="species:ncbi:9606">patient</span>
Different corneal immunophenotypes among affected members of a family with MCD. A: Corneal section from patient 62 having MCD type II, showing staining for AgKS throughout the stroma and in keratocytes. B: Corneal section from patient 63 from the same family, having MCD type IA. Staining for AgKS is seen only in corneal keratocytes, and is completely absent in the stroma (details in Table 1; stained with DAB, counterstained with hematoxylin-eosin and periodic acid Schiff, 400X).
###end p 30
###begin title 31
Correlations between mutations and immunophenotypes
###end title 31
###begin title 32
MCD type I
###end title 32
###begin p 33
###xml 36 43 36 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Of the 27 families with MCD type I (Table 1), 10 different missense mutations were found in 11 families, three nonsense mutations in three families, five frameshift mutations in seven families, and two in-frame insertion mutations in six families. Homozygous mutations were identified in all families.
###end p 33
###begin p 34
###xml 126 133 126 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Similar mutational heterogeneity was observed in families grouped as either MCD type I or MCD IA based on serum Ag KS levels (Table 1).
###end p 34
###begin title 35
MCD type IA
###end title 35
###begin p 36
###xml 208 215 208 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Of the five families classified as MCD type IA based on corneal AgKS, four families had three missense mutations with one mutation, Asp221Glu, in two families, and the fifth family had an in-frame insertion (Table 1).
###end p 36
###begin title 37
MCD type II
###end title 37
###begin p 38
###xml 266 273 266 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 114 121 <span type="species:ncbi:9606">patient</span>
###xml 189 196 <span type="species:ncbi:9606">patient</span>
###xml 254 261 <span type="species:ncbi:9606">patient</span>
MCD type II was found in association with a single heterozygous frameshift mutation (Phe67SerfsX3) in one family (patient 39), two homozygous mutations, Trp2Ter and Leu3Met, in one family (patient 40), and with no detectable mutations in another family (patient 41; Table 1).
###end p 38
###begin title 39
Atypical immunophenotypes
###end title 39
###begin p 40
###xml 43 50 43 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 242 249 242 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 184 191 <span type="species:ncbi:9606">patient</span>
Patients with 'atypical' immunophenotypes (Table 1) showed missense mutations (6 families), nonsense mutations (1 family), and no detectable mutation (1 family). Of these, one family (patient 56) had a single heterozygous mutation (Ser98Leu; Table 1).
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
This study examined immunophenotypes in MCD in relation to the mutational status of CHST6 in MCD patients of Indian origin. The existence of distinct immunophenotypes of MCD has been well documented [10-12,20], and yet their biological or clinical significance remains unclear. Though a mutation in CHST6, presumed to lead to the absence of sulfation of KS precursors, is established as the cause of MCD, the presence of sulfated epitopes that are recognizable by the 5D4 monoclonal antibody in the cornea and/or serum of a subset of MCD patients suggests a further level of complexity in the pathogenesis of MCD. Understanding the molecular basis of the MCD immunophenotypes may lead to a better comprehension of the pathobiology of this inherited corneal disease.
###end p 42
###begin p 43
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 342 350 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 760 768 <span type="species:ncbi:9606">patients</span>
The present study revealed that MCD type I is the most frequent immunophenotype in Indian patients. Taking into account those patients with their corneal and serum levels of AgKS evaluated, MCD type I, which was seen in 63% of patients (22/35 patients or 20/31 families), was the most common followed by MCD type IA, which was seen in 14% of patients (5/35 patients or 4/31 families), and then MCD type II, which was seen in 3% of patients (1/35 patients or 1/31 families). The predominance of MCD type I over other types is similar to that found in studies on MCD patients from various regions including Iceland, Saudi Arabia, southern India, and the United States [11,12,15,21,22]. A similar frequency of MCD types I and IA was reported in a study on German patients [23].
###end p 43
###begin p 44
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 581 588 <span type="species:ncbi:9606">patient</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
An unusual feature observed in the present study was that seven families showed 'atypical' immunophenotypes in which the values of serum AgKS ranged from 19 ng/ml to 388 ng/ml, although immunohistochemical analysis of these corneal sections showed little or no reactivity to AgKS, which would depict immunophenotypes MCD type I or MCD type IA. While the reasons for this are not currently understood, it may indicate further immunophenotypic heterogeneity in MCD. Complex immunophenotypes were also observed in a previous study by Iida-Hasegawa and coworkers [24] who found that a patient with serum AgKS corresponding to MCD type I had positive reactivity to AgKS in the stroma and extracellular accumulations. Moreover, patients with serum AgKS levels compatible with MCD type II in their study showed no stromal reactivity to AgKS on immunohistochemistry [24].
###end p 44
###begin p 45
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 768 775 768 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 909 916 909 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
###xml 655 663 <span type="species:ncbi:9606">patients</span>
###xml 881 889 <span type="species:ncbi:9606">patients</span>
###xml 952 959 <span type="species:ncbi:9606">patient</span>
###xml 961 968 <span type="species:ncbi:9606">patient</span>
###xml 1054 1062 <span type="species:ncbi:9606">patients</span>
We found no clear-cut correlations between immunophenotypes and mutations in CHST6. Mutational heterogeneity was seen within each subtype of MCD. The same mutation was found to be associated with more than one immunophenotype. Of these, one mutation, Asp221Tyr, was found in patients from a single family with all three immunophenotypes while two other mutations, Trp219-220ins and Phe107Ser, were associated with MCD types I and IA. There were two recurrent mutations in our series, each found in six families, an insertion mutation, Trp219-220ins, and a missense mutation, Asp221Glu. Each was associated predominantly with one immunophenotype among the patients studied. Trp219-220ins was present in five families with MCD type I and in one family with MCD type IA (Table 1). The Asp221Glu mutation was predominantly found in association with a corneal phenotype of MCD type IA (patients 36-38, 55, 59, 61; Table 1) as well as with MCD type I in one patient (patient 60). However, serum AgKS values in three of these families showed atypical patterns (patients 55, 59, 60).
###end p 45
###begin p 46
###xml 474 479 474 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
It is noteworthy that all three MCD subtypes were observed in one family, which was associated with the mutation, Asp221Tyr. The concordance between serum AgKS and corneal AgKS reactivity in each member of this family makes it unlikely that the variable immunoreactivity within the family is due to artifacts of detection. The presence of both MCD types I and II has also been noted previously in an Icelandic family, although with different but overlapping combinations of CHST6 alleles [25,26].
###end p 46
###begin p 47
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 346 348 346 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 659 666 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 698 703 698 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 717 723 717 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table1</xref>
###xml 972 979 972 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 1121 1126 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 1208 1215 1208 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 647 654 <span type="species:ncbi:9606">patient</span>
###xml 705 712 <span type="species:ncbi:9606">patient</span>
###xml 872 879 <span type="species:ncbi:9606">patient</span>
###xml 960 967 <span type="species:ncbi:9606">patient</span>
###xml 1009 1017 <span type="species:ncbi:9606">patients</span>
###xml 1196 1203 <span type="species:ncbi:9606">patient</span>
There were very few patients with MCD type II in our series. A recurrent feature observed in different studies to date is that patients with MCD type II have no detectable mutations in the coding region and/or upstream region on one or both alleles of CHST6 [14,15,21,22], although contradictory observations have been reported in some cases [14,26]. The predicted effect of mutations in the upstream (regulatory) regions and the absence of coding region mutations is that CHST6 alleles in MCD type II would retain more enzymatic activity as compared to those responsible for MCD type I. We noted the occurrence of a single heterozygous mutation (patient 39; Table 1) or no detectable mutations in CHST6 (patient 41; Table1) in two out of three families with MCD type II. It is worth noting that the other occurrence of a single heterozygous change in our series was in a patient having a corneal phenotype of MCD type IA but with normal levels of serum AgKS (patient 56; Table 1). Previous analysis in these patients with an absence of mutations in the coding region failed to detect mutations in the upstream region of CHST6 [16,17]. Apart from these, one family with MCD type II in our study (patient 40; Table 1) had a double homozygous change of Trp2X and Leu3Met. An interesting possibility that needs to be explored further is that though a nonsense mutation Trp2X occurs at the second codon, a Leu3Met mutation in the next codon may generate a protein that is at least partially active due to re-initiation at codon 3 of the wild type protein.
###end p 47
###begin p 48
###xml 206 211 206 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1022 1027 1022 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 904 912 <span type="species:ncbi:9606">patients</span>
In the background of the available literature and the results of the present study, the molecular basis of different immunophenotypes of MCD may not be readily explainable only on the basis of mutations in CHST6. KS is one of the major GAGs of the corneal stroma and plays an important role in corneal transparency. The variable presence of sulfated KS in cornea or serum of patients with CHST6 mutations may be explained by a possible redundancy in KS sulfation activity both within the cornea and other tissues. Corneal N-acetyl glucosamine 6-sulfotransferase has been shown to efficiently catalyze the sulfation of endothelial mucin, which is the substrate for intestinal N-acetyl glucosamine sulfotransferase, thus showing that there is an overlap in activity with the intestinal sulfotransferase [27]. These possibilities, however, do not explain the absence of any clinical differences between MCD patients with different immunophenotypes. A biochemical evaluation of the enzymatic activities of proteins encoded by CHST6 mutations associated with MCD type II versus mutations associated with MCD type I may reveal whether there are differences in activity between the two groups of mutants.
###end p 48
###begin p 49
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHST6</italic>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Data from the present study, which involved analysis of a large series of MCD patients from the same geographic origin, show complexity of immunophenotypes in MCD and suggest further immunophenotypic heterogeneity than previously described. The different immunophenotypes might be determined by factors other than or in addition to CHST6 mutations.
###end p 49
###begin title 50
Acknowledgments
###end title 50
###begin p 51
This work was supported by a grant from the Department of Biotechnology, Government of India, and by the Hyderabad Eye Research Foundation. A.S. was supported by a fellowship from the Council for Scientific and Industrial Research, India.
###end p 51
###begin title 52
References
###end title 52
###begin article-title 53
Macular corneal dystrophy: failure to synthesize a mature keratan sulfate proteoglycan.
###end article-title 53
###begin article-title 54
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Abnormalities of proteoglycans and glycoproteins synthesized by corneal organ cultures derived from patients with macular corneal dystrophy.
###end article-title 54
###begin article-title 55
Defective processing of keratan sulfate in macular corneal dystrophy.
###end article-title 55
###begin article-title 56
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Serum sulfotransferase levels in patients with macular corneal dystrophy type I.
###end article-title 56
###begin article-title 57
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
Measurement of activities of human serum sulfotransferases which transfer sulfate to the galactose residues of keratan sulfate and to the nonreducing end N acetylglucosamine residues of N-acetyllactosamine trisaccharide: comparison between normal controls and patients with macular corneal dystrophy.
###end article-title 57
###begin article-title 58
Decreased GlcNAc 6-O-sulfotransferase activity in the cornea with macular corneal dystrophy.
###end article-title 58
###begin article-title 59
Linkage of a gene for macular corneal dystrophy to chromosome 16.
###end article-title 59
###begin article-title 60
Macular corneal dystrophy type I and type II are caused by distinct mutations in a new sulphotransferase gene.
###end article-title 60
###begin article-title 61
Immunohistochemical evidence of heterogeneity in macular corneal dystrophy.
###end article-title 61
###begin article-title 62
Macular corneal dystrophy in Saudi Arabia: a study of 56 cases and recognition of a new immunophenotype.
###end article-title 62
###begin article-title 63
###xml 98 106 <span type="species:ncbi:9606">patients</span>
Macular corneal dystrophy in Iceland. A clinical, genealogic, and immunohistochemical study of 28 patients.
###end article-title 63
###begin article-title 64
Ultrastructural localization of sulfated and unsulfated keratan sulfate in normal and macular corneal dystrophy type I.
###end article-title 64
###begin article-title 65
Truncating mutations in the carbohydrate sulfotransferase 6 gene (CHST6) result in macular corneal dystrophy.
###end article-title 65
###begin article-title 66
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Novel mutations in the carbohydrate sulfotransferase (CHST6) gene in American patients with macular corneal dystrophy.
###end article-title 66
###begin article-title 67
Novel mutations of the carbohydrate sulfotransferase-6 (CHST6) gene causing macular corneal dystrophy in India.
###end article-title 67
###begin article-title 68
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Allelic heterogeneity of the carbohydrate sulfotransferase-6 gene in patients with macular corneal dystrophy.
###end article-title 68
###begin article-title 69
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabeled antibody (PAP) procedures.
###end article-title 69
###begin article-title 70
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Absence of normal keratan sulfate in the blood of patients with macular corneal dystrophy.
###end article-title 70
###begin article-title 71
Sulfation patterns of keratan sulfate in different macular corneal dystrophy immunophenotypes using three different probes.
###end article-title 71
###begin article-title 72
Novel mutations in the CHST6 gene associated with macular corneal dystrophy in southern India.
###end article-title 72
###begin article-title 73
CHST6 mutations in North American subjects with macular corneal dystrophy: a comprehensive molecular genetic review.
###end article-title 73
###begin article-title 74
Immunohistochemical classification of primary and recurrent macular corneal dystrophy in Germany: subclassification of immunophenotype IA using a novel keratan sulfate antibody.
###end article-title 74
###begin article-title 75
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Mutations in CHST6 gene in patients with macular corneal dystrophy: immunohistochemical evidence of heterogeneity.
###end article-title 75
###begin article-title 76
Different mutations in carbohydrate sulfotransferase 6 (CHST6) gene cause macular corneal dystrophy types I and II in a single sibship.
###end article-title 76
###begin article-title 77
Macular corneal dystrophy types I and II are caused by distinct mutations in the CHST6 gene in Iceland.
###end article-title 77
###begin article-title 78
###xml 50 51 50 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
Sulfation of endothelial mucin by corneal keratan N-acetylglucosamine 6-O-sulfotransferase (GST-4beta).
###end article-title 78

